Related Experiment Video
Updated: Dec 13, 2025
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
Recombinant Bispecific Antibodies to the Human ErbB2 Receptor and Interferon-Beta
A A Panina1, V S Rybchenko1, O N Solopova2,3
1Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.
Abstract:
The development of and research into new therapies that can selectively and effectively destroy tumor cells that overexpress the ErbB2 receptor is a pressing task. Recently, research into the use of type I interferons in the treatment of cancer has intensified. Cytokine therapy is aimed at activating the cells of the immune system to fight tumors, but it has drawbacks that limit its use because of a number of side effects the severity of which varies depending on the dosage and type of used cytokine. At the moment, a number of studies are being conducted regarding the use of IFNβ in oncology. The studies are aimed at mitigating the systemic action of this cytokine. The immunocytokine complex made of a bispecific antibody against the ErbB2 receptor and recombinant IFNβ developed in this study underlies the mechanism meant to avoid the systemic action of this cytokine. Part of this study focuses on the development of full-length antibodies that bind to the ErbB2 receptor on the one hand, and bind and neutralize IFNβ, on the other hand, which allows us to consider the antibodies as a means of cytokine delivery to tumor cells.
Insights
This study introduces a novel immunocytokine complex for targeted cancer therapy. It combines a bispecific antibody with interferon-beta (IFNβ) to specifically target ErbB2-overexpressing tumor cells, reducing side effects.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Targeting ErbB2-overexpressing tumors requires selective therapies.
- Type I interferons, like interferon-beta (IFNβ), show promise in cancer treatment but have dose-dependent side effects.
- Mitigating systemic cytokine toxicity is crucial for effective cancer immunotherapy.
Purpose of the Study:
- To develop a novel immunocytokine complex for targeted delivery of IFNβ to ErbB2-positive tumors.
- To create bispecific antibodies capable of binding both ErbB2 receptors and neutralizing IFNβ.
- To investigate a strategy for reducing systemic side effects associated with IFNβ cancer therapy.
Main Methods:
- Development of a bispecific antibody targeting the ErbB2 receptor.
- Conjugation of recombinant IFNβ to the bispecific antibody to form an immunocytokine complex.
- Engineering of full-length antibodies for dual binding to ErbB2 and IFNβ.
Main Results:
- Successful development of an immunocytokine complex comprising a bispecific antibody and IFNβ.
- Demonstrated potential for targeted delivery of IFNβ to ErbB2-expressing tumor cells.
- Antibodies designed to bind and neutralize IFNβ, facilitating targeted delivery.
Conclusions:
- The developed immunocytokine complex offers a potential strategy to enhance the efficacy of IFNβ in treating ErbB2-positive cancers.
- This approach may mitigate systemic toxicity by concentrating the therapeutic agent at the tumor site.
- Bispecific antibodies serve as effective carriers for targeted cytokine delivery in cancer therapy.
Related Concept Videos
00:42Cross-reactivity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:27Tumor Immunotherapy